Sana Biotechnologyincis A Clinical Stage Biotechnology Company Based In Seattlewashingtonwith Additional Operations In Cambridgemassachusettsand South San Franciscofounded In 2018Sana Focuses On Developing Engineered Cell Therapies To Address The Root Causes Of Diseases By Repairingcontrollingor Replacing Damaged Cellsthe Company Aims To Create Transformative Medicines For Conditions Such As Cancerdiabetesand Autoimmune Disorders Sana Operates Through Three Primary Platformsin Vivo Deliverywhich Uses Lipid Nanoparticles And Adeno Associated Viruses To Deliver Therapeutic Genes Directly Into Cellsex Vivo Cell Engineeringwhich Modifies Cells Outside The Body To Enhance Their Therapeutic Propertiesand The Hypoimmune Platformwhich Engineers Donor Cells To Evade Immune Rejection For Allogeneic Therapiesthe Company Is Advancing A Pipeline Of Preclinical And Clinical Stage Candidateswith Significant Investments In Research And Development To Support Its Innovative Approaches
